CAR Specific Cellular Immune Response Assay (T-Cell Response) Service

Q: Q1: Why is it necessary to conduct CAR-T cellular immune response monitoring?

A1: As a form of "living drug," the in vivo expansion, persistence, and functional status of CAR-T cells directly dictate both therapeutic efficacy and toxicity risks. Monitoring these cellular dynamics serves as a cornerstone of clinical management by allowing clinicians to predict efficacy through expansion kinetics proactively manage major adverse events like Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) triggered by immune hyperactivation, and ultimately guide personalized interventions for high-risk patients.

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite the transformative potential of CAR-T cell therapies, accurately quantifying antigen-specific T cell activation, proliferation, and effector function remains a significant challenge, often hampered by low-frequency responses and complex matrix effects. Our CAR-Specific Cellular Immune Response Assay (T-Cell Response) provides a robust, standardized platform designed to precisely measure CAR-dependent T cell activity against target antigens. We offer a comprehensive service encompassing assay design, sample processing, multiparameter flow cytometric analysis, and detailed data interpretation, tailored to both pre-clinical and clinical samples. Our service delivers high sensitivity, reproducibility, and actionable insights, enabling you to reliably evaluate product potency, monitor patient immune responses, and accelerate your translational research with confidence.

Introduction

Chimeric antigen receptor (CAR) therapy represents a paradigm shift in cancer immunotherapy, genetically engineering autologous or allogeneic T cells to recognize and eliminate malignant cells through synthetic receptor-mediated targeting. The CAR-specific cellular immune response, encompassing T-cell activation, proliferation, cytokine secretion, and cytotoxic degranulation upon antigen engagement, serves as the critical functional readout for evaluating product potency, safety, and clinical predictivity, making its precise measurement indispensable for both preclinical development and translational research.

Fig.1 CAR-T cells mediate tumor recognition via binding to tumor-associated antigens. (OA Literature) Fig.1 CAR-T cells identify tumor cells via targeted binding to tumor-associated antigens.¹

Our Service

Our CAR-Specific Cellular Immune Response Assay leverages advanced flow cytometry and cell-based platforms to quantify T-cell reactivity against CAR constructs. By utilizing optimized, high-purity overlapping peptide pools, this highly sensitive assay assesses potential cellular immunogenicity, mitigates background noise, and tracks in vivo CAR-T persistence. We provide actionable, regulatory-compliant data to optimize your cell therapy candidates and de-risk clinical development.

What We Can Offer

We provide a comprehensive suite of advanced cellular immunogenicity assays designed to precisely quantify, phenotypically characterize, and functionally evaluate host T cell mediated immune responses against CAR constructs, ensuring robust safety and efficacy profiling throughout your clinical development.

Featured services of CAR-specific cellular immune response assay at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Peripheral Blood Mononuclear Cells (PBMCs).
CAR-specific overlapping peptide pools or CAR-expressing target cells.

Key Steps:

Workflow of CAR-specific cellular immune response assay at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Subpopulation phenotyping and cytokine polyfunctionality of responding T cells.
Determination results.

Key Advantages

Direct Immunogenicity Assessment: Unlike standard antibody-based assays, this analysis directly captures cellular immune responses against the CAR protein to effectively predict potential CAR-T cell rejection and clearance in vivo.
High Sensitivity and Quantitative Precision: By combining optimized peptide pool stimulation with advanced detection tech, this assay quantifies extremely low frequencies of anti-CAR specific T cells in peripheral blood with single-cell-level sensitivity.
Deep Multi-Dimensional Functional Profiling: Our assay comprehensively resolves responding T-cell subsets and evaluates their cytokine polyfunctionality to gauge the precise intensity of the host mediated immune clearance.
Guidance for Structural Design Optimization: As a powerful R&D screening tool, our assay quantitatively evaluates the immunogenicity profiles of various CAR constructs to accelerate the selection of safer, more tolerable candidates.

FAQ

Q1: Why is it necessary to conduct CAR-T cellular immune response monitoring?

A1: As a form of "living drug," the in vivo expansion, persistence, and functional status of CAR-T cells directly dictate both therapeutic efficacy and toxicity risks. Monitoring these cellular dynamics serves as a cornerstone of clinical management by allowing clinicians to predict efficacy through expansion kinetics proactively manage major adverse events like Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) triggered by immune hyperactivation, and ultimately guide personalized interventions for high-risk patients.

Q2: How should the "peptide pools" be designed for the assay?

A2: Because CAR is a recombinant fusion protein, its primary immunogenicity stems from the extracellular binding domain as well as the junction sites of the hinge and co-stimulatory domains. To capture all potential T cell epitopes across these vulnerable regions, the assay typically utilizes 15-mer overlapping peptide pools, where each peptide consists of 15 amino acids that overlap with the adjacent sequence by 11 amino acids, effectively screening the entire immunogenic sequence for cellular reactivity.

Why Choose Us?

Accelerate your regulatory filings with our industry-leading cell-based assays. We offer fully compliant flow cytometry platforms, including advanced intracellular cytokine staining (ICS), powered by optimized, high-purity peptide pools. Partner with our immunology experts for ultra-sensitive immunogenicity profiling, rigorous background mitigation, and customized tracking of CAR-T persistence with unparalleled data fidelity.

Customer Reviews

"We utilized this CAR-specific cellular immune response assay to evaluate the immunogenicity profile of our lead candidate. The assay offered exceptional sensitivity and zero baseline interference, providing the clean, robust data required for our regulatory dossier. Their scientific team’s expertise in peptide pool design made all the difference." Dr. Ar* T*.

"Tracking host T cell responses against our CAR construct was critical for understanding our persistence data. This service delivered high-throughput, highly reproducible intracellular cytokine staining results that perfectly complemented our PK tracking. It has become an indispensable tool in our analytical toolkit." PhD. S* J*.

How to contact us?

Ready to elevate your CAR-T pipeline? Partner with our immunology experts to ensure robust, regulatory-compliant cellular immune response monitoring. Contact our dedicated project team today to discuss your study design, receive expert technical consultation, and obtain a tailored quotation that accelerates your cellular therapy toward clinical success.

Reference

Majumder, Avisek. "Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures." Cancers vol. 16,1 39. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/cancers16010039.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.